Literature DB >> 32510802

Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.

Mojun Zhu1, Mohamad Bassam Sonbol2, Thorvardur Halfdanarson1, Timothy Hobday1, Daniel Ahn2, Wen Wee Ma1, Tanios Bekaii-Saab2.   

Abstract

Lutetium-177-dotatate (177 Lu-dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of the NETTER-1 trial for grade 1-2 midgut NETs. Here, we present a patient with a grade 3 pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to 177 Lu-dotatate. © AlphaMed Press 2020.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32510802      PMCID： PMC7418337          DOI： 10.1634/theoncologist.2020-0029

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159            Impact factor:   5.837


  10 in total

Review 1.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

2.  Whole-genome landscape of pancreatic neuroendocrine tumours.

Authors:  Aldo Scarpa; David K Chang; Katia Nones; Vincenzo Corbo; Ann-Marie Patch; Peter Bailey; Rita T Lawlor; Amber L Johns; David K Miller; Andrea Mafficini; Borislav Rusev; Maria Scardoni; Davide Antonello; Stefano Barbi; Katarzyna O Sikora; Sara Cingarlini; Caterina Vicentini; Skye McKay; Michael C J Quinn; Timothy J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne McLean; Craig Nourse; Ehsan Nourbakhsh; Peter J Wilson; Matthew J Anderson; J Lynn Fink; Felicity Newell; Nick Waddell; Oliver Holmes; Stephen H Kazakoff; Conrad Leonard; Scott Wood; Qinying Xu; Shivashankar Hiriyur Nagaraj; Eliana Amato; Irene Dalai; Samantha Bersani; Ivana Cataldo; Angelo P Dei Tos; Paola Capelli; Maria Vittoria Davì; Luca Landoni; Anna Malpaga; Marco Miotto; Vicki L J Whitehall; Barbara A Leggett; Janelle L Harris; Jonathan Harris; Marc D Jones; Jeremy Humphris; Lorraine A Chantrill; Venessa Chin; Adnan M Nagrial; Marina Pajic; Christopher J Scarlett; Andreia Pinho; Ilse Rooman; Christopher Toon; Jianmin Wu; Mark Pinese; Mark Cowley; Andrew Barbour; Amanda Mawson; Emily S Humphrey; Emily K Colvin; Angela Chou; Jessica A Lovell; Nigel B Jamieson; Fraser Duthie; Marie-Claude Gingras; William E Fisher; Rebecca A Dagg; Loretta M S Lau; Michael Lee; Hilda A Pickett; Roger R Reddel; Jaswinder S Samra; James G Kench; Neil D Merrett; Krishna Epari; Nam Q Nguyen; Nikolajs Zeps; Massimo Falconi; Michele Simbolo; Giovanni Butturini; George Van Buren; Stefano Partelli; Matteo Fassan; Kum Kum Khanna; Anthony J Gill; David A Wheeler; Richard A Gibbs; Elizabeth A Musgrove; Claudio Bassi; Giampaolo Tortora; Paolo Pederzoli; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2017-02-15       Impact factor: 49.962

Review 3.  The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.

Authors:  Frediano Inzani; Gianluigi Petrone; Guido Rindi
Journal:  Endocrinol Metab Clin North Am       Date:  2018-07-11       Impact factor: 4.741

Review 4.  Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.

Authors:  Aatur D Singhi; David S Klimstra
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

5.  First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

6.  The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.

Authors:  Massimo Milione; Patrick Maisonneuve; Francesca Spada; Alessio Pellegrinelli; Paola Spaggiari; Luca Albarello; Eleonora Pisa; Massimo Barberis; Alessandro Vanoli; Roberto Buzzoni; Sara Pusceddu; Laura Concas; Fausto Sessa; Enrico Solcia; Carlo Capella; Nicola Fazio; Stefano La Rosa
Journal:  Neuroendocrinology       Date:  2016-03-05       Impact factor: 4.914

7.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.

Authors:  T R Halfdanarson; K G Rabe; J Rubin; G M Petersen
Journal:  Ann Oncol       Date:  2008-05-30       Impact factor: 32.976

Review 8.  The therapeutic significance of mutational signatures from DNA repair deficiency in cancer.

Authors:  Jennifer Ma; Jeremy Setton; Nancy Y Lee; Nadeem Riaz; Simon N Powell
Journal:  Nat Commun       Date:  2018-08-17       Impact factor: 14.919

9.  The 2019 WHO classification of tumours of the digestive system.

Authors:  Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

10.  A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.

Authors:  Sandip P Patel; Young Kwang Chae; Megan Othus; Francis J Giles; Donna E Hansel; Preet Paul Singh; Annette Fontaine; Manisha H Shah; Anup Kasi; Tareq Al Baghdadi; Marc Matrana; Zoran Gatalica; W Michael Korn; Jourdain Hayward; Christine McLeod; Helen X Chen; Elad Sharon; Edward Mayerson; Christopher W Ryan; Melissa Plets; Charles D Blanke; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2020-01-22       Impact factor: 12.531
  10 in total
  1 in total

1.  Update to "Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors".

Authors:  Mojun Zhu; Tanios Bekaii-Saab
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.